Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Barker

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Nature Reviews. Drug Discovery|July 7, 2018
The evolution of adaptiveness: balancing speed and evidenceHans-Georg Eichler, Richard Barker, Nicola Bedlington, et al.
Systematic Reviews|June 28, 2017
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocolDavid Pettitt, Zeeshaan Arshad, Benjamin Davies, et al.
Molecular Pharmaceutics|February 20, 2026
An Expert's View on the Application of TIM Technology in the Development of Oral Drug ProductsÁlvaro López Mármol, Richard Barker, Mirko Koziolek, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|April 21, 2024
Leveraging natural capital accounting to support businesses with nature-related risk assessments and disclosuresJane Carter Ingram, Emily J McKenzie, Kenneth J Bagstad, et al.
Molecular Medicine (Cambridge, Mass.)|February 10, 2017
miR-155 Modifies Inflammation, Endothelial Activation and Blood-Brain Barrier Dysfunction in Cerebral MalariaKevin Richard Barker, Ziyue Lu, Hani Kim, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|July 16, 2019
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juicesXavier J H Pepin, Andrea J Moir, James C Mann, et al.
Nature Communications|June 11, 2024
Astronaut omics and the impact of space on the human body at scaleLindsay A Rutter, Henry Cope, Matthew J MacKay, et al.
Plos One|January 13, 2022
Inpatient COVID-19 mortality has reduced over time: Results from an observational cohortKatie Bechman, Mark Yates, Kirsty Mann, et al.
Pharmaceutics|May 4, 2026
TIM-1 and Tiny-TIM as Robust In Vitro Models for Oral Biopharmaceutics: Evidence from an International Ring StudyConnor O'Farrell, Robert Havenaar, Mark McAllister, et al.
Nature Medicine|March 13, 2025
Cities, communities and clinics can be testbeds for human exposome and aging researchTina Woods, Nic Palmarini, Lynne Corner, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Nature Reviews. Drug Discovery|July 7, 2018
The evolution of adaptiveness: balancing speed and evidenceHans-Georg Eichler, Richard Barker, Nicola Bedlington, et al.
Systematic Reviews|June 28, 2017
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocolDavid Pettitt, Zeeshaan Arshad, Benjamin Davies, et al.
Molecular Pharmaceutics|February 20, 2026
An Expert's View on the Application of TIM Technology in the Development of Oral Drug ProductsÁlvaro López Mármol, Richard Barker, Mirko Koziolek, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|April 21, 2024
Leveraging natural capital accounting to support businesses with nature-related risk assessments and disclosuresJane Carter Ingram, Emily J McKenzie, Kenneth J Bagstad, et al.
Molecular Medicine (Cambridge, Mass.)|February 10, 2017
miR-155 Modifies Inflammation, Endothelial Activation and Blood-Brain Barrier Dysfunction in Cerebral MalariaKevin Richard Barker, Ziyue Lu, Hani Kim, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|July 16, 2019
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juicesXavier J H Pepin, Andrea J Moir, James C Mann, et al.
Nature Communications|June 11, 2024
Astronaut omics and the impact of space on the human body at scaleLindsay A Rutter, Henry Cope, Matthew J MacKay, et al.
Plos One|January 13, 2022
Inpatient COVID-19 mortality has reduced over time: Results from an observational cohortKatie Bechman, Mark Yates, Kirsty Mann, et al.
Pharmaceutics|May 4, 2026
TIM-1 and Tiny-TIM as Robust In Vitro Models for Oral Biopharmaceutics: Evidence from an International Ring StudyConnor O'Farrell, Robert Havenaar, Mark McAllister, et al.
Nature Medicine|March 13, 2025
Cities, communities and clinics can be testbeds for human exposome and aging researchTina Woods, Nic Palmarini, Lynne Corner, et al.
Pageof 7